PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsUpadacitinib
Rinvoq(upadacitinib)
Rinvoq (upadacitinib) is a small molecule pharmaceutical. Upadacitinib was first approved as Rinvoq on 2019-08-16. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Rinvoq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Upadacitinib
Tradename
Company
Number
Date
Products
RINVOQAbbVieN-211675 RX2019-08-16
3 products, RLD
RINVOQ LQAbbVieN-218347 RX2024-04-26
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
rinvoqNew Drug Application2024-04-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
UPADACITINIB, RINVOQ, ABBVIE
2026-05-18I-919
2025-04-29I-888
2025-03-16I-886
2025-01-14I-883
2024-12-14I-880
2024-08-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Upadacitinib, Rinvoq, Abbvie
115649222038-03-09U-3624
116074112038-03-09U-3341
99510802036-10-17DS, DP
99634592036-10-17DP
102023932036-10-17DP
103440362036-10-17DP
105191642036-10-17DP
105501262036-10-17U-3298
105974002036-10-17U-3255
107308832036-10-17DP
109819232036-10-17DP
109819242036-10-17DP
109950952036-10-17U-3298
111865842036-10-17DP
111986972036-10-17DP
113651982036-10-17U-3275
115120922036-10-17U-3275, U-3371, U-3487
115249642036-10-17U-3371
115356242036-10-17U-3255
115356252036-10-17U-3298
115356262036-10-17U-3298
116614252036-10-17DS, DP
116800692036-10-17DS, DP
117186272036-10-17DS, DP
117673262036-10-17U-3298
117731052036-10-17DS, DP
117731062036-10-17U-3275, U-3371, U-3487
117808472036-10-17DP
117808482036-10-17U-3371
117878152036-10-17DP
117951752036-10-17U-3255
89626292031-01-15DPU-3255, U-3275, U-3341, U-3371, U-3624
RE472212030-12-01DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA44: Upadacitinib
HCPCS
No data
Clinical
Clinical Trials
128 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ArthritisD001168EFO_0005856M05-M14161311131
Atopic dermatitisD003876EFO_0000274L20111211227
DermatitisD003872—L30.9111211227
EczemaD004485—L30.9111211126
Rheumatoid arthritisD001172EFO_0000685M06.9—6101824
Psoriatic arthritisD015535EFO_0003778L40.5——2147
SpondylarthritisD025241———11147
SpondylitisD013166—M46.9—11147
PrurigoD011536—L28.2———112
NeurodermatitisD009450—L28.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K51—15—510
ColitisD003092EFO_0003872K52.9—15—510
Crohn diseaseD003424EFO_0000384K50—24—410
UlcerD014456MPATH_579——15—49
Systemic lupus erythematosusD008180EFO_0002690M32—21——3
Rheumatic diseasesD012216—M79.0——3——3
Hidradenitis suppurativaD017497—L73.2—11——2
HidradenitisD016575———11——2
Axial spondyloarthritisD000089183————1—12
ArteritisD001167EFO_0009011I77.6——2——2
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ankylosing spondylitisD013167EFO_0003898M45—1——23
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameUpadacitinib
INNupadacitinib
Description
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Identifiers
PDB—
CAS-ID1310726-59-0
RxCUI—
ChEMBL IDCHEMBL3622821
ChEBI ID—
PubChem CID58557659
DrugBankDB15091
UNII ID4RA0KN46E0 (ChemIDplus, GSRS)
Target
Agency Approved
JAK1
JAK1
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Alternate
JAK3
JAK3
JAK2
JAK2
TYK2
TYK2
Organism
Homo sapiens
Gene name
JAK3
Gene synonyms
NCBI Gene ID
3718
Protein name
tyrosine-protein kinase JAK3
Protein synonyms
JAK-3, Janus kinase 3, Janus kinase 3 (a protein tyrosine kinase, leukocyte), L-JAK, Leukocyte janus kinase
Uniprot ID
Q9Y6S2
Mouse ortholog
Jak3 (16453)
tyrosine-protein kinase JAK3 (Q8BYU2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Rinvoq – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,168 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rinvoq
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
51,070 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use